Copper
Breast Neoplasm Female
The Institute of Molecular and Translational Medicine, Czech RepublicPhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 35/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Breast Neoplasm Female cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Peg-G-Csf Kexing Biopharm Co., Ltd. | Phase 3 | B |
Nivolumab Providence Health & Services | Phase 2 | B |
5-ala SBI ALApharma Canada, Inc. | Phase 3 | CCC |
HYALURONATE Erin Newton | Phase 2 | CCC |
AK105 Liaoning Cancer Hospital & Institute | Phase 2 | CCC |
View all 18 →
Same molecule, other indications
Copper is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →